Volitionrx LTD (NYSEMKT:VNRX) Institutional Investors Sentiment Index Worsens in Q2 2019

VolitionRx Limited (NYSEAMERICAN:VNRX) Logo

Sentiment for Volitionrx LTD (NYSEMKT:VNRX)

Volitionrx LTD (NYSEMKT:VNRX) institutional sentiment decreased to 1.5 in Q2 2019. Its down -0.17, from 1.67 in 2019Q1. The ratio has dropped, as 9 institutional investors started new or increased equity positions, while 6 cut down and sold their stock positions in Volitionrx LTD. The institutional investors in our partner’s database reported: 3.01 million shares, down from 3.03 million shares in 2019Q1. Also, the number of institutional investors holding Volitionrx LTD in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 2 Reduced: 4 Increased: 7 New Position: 2.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers. The company has market cap of $168.13 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It currently has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

The stock increased 0.75% or $0.03 during the last trading session, reaching $4.02. About 20,995 shares traded. VolitionRx Limited (NYSEMKT:VNRX) has risen 137.36% since September 13, 2018 and is uptrending. It has outperformed by 137.36% the S&P500.

Analysts await VolitionRx Limited (NYSEAMERICAN:VNRX) to report earnings on November, 6. They expect $-0.11 EPS, up 21.43 % or $0.03 from last year’s $-0.14 per share. After $-0.11 actual EPS reported by VolitionRx Limited for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Lagoda Investment Management L.P. holds 7.07% of its portfolio in VolitionRx Limited for 1.94 million shares. Garrison Bradford & Associates Inc owns 15,500 shares or 0.06% of their US portfolio. Moreover, Leisure Capital Management has 0.04% invested in the company for 13,255 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. Hartford Financial Management Inc., a Connecticut-based fund reported 8,300 shares.

Since January 1, 0001, it had 3 insider buys, and 0 insider sales for $497,242 activity.

More notable recent VolitionRx Limited (NYSEAMERICAN:VNRX) news were published by: Finance.Yahoo.com which released: “VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update – Yahoo Finance” on August 12, 2019, also Prnewswire.com with their article: “Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock – PRNewswire” published on July 24, 2019, Prnewswire.com published: “VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China – PRNewswire” on March 28, 2019. More interesting news about VolitionRx Limited (NYSEAMERICAN:VNRX) were released by: Prnewswire.com and their article: “VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update – PRNewswire” published on May 08, 2019 as well as Prnewswire.com‘s news article titled: “VolitionRx Announces $9 Million Private Placement – PR Newswire” with publication date: August 08, 2018.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.